

## Ipilimumab Biosimilar - Research Grade ICH4025

### Product Information

<b>Catalog Number:</b>	ICH4025
<b>Product:</b>	Low endotoxin, biosimilar antibody
<b>Target:</b>	CTLA-4
<b>Isotype:</b>	IgG1 kappa
<b>Other names:</b>	Ctla4, Cytotoxic T-lymphocyte protein 4, CD152
<b>Host:</b>	Humanized
<b>Species Reactivity:</b>	Human
<b>Specificity:</b>	Detects human CTLA-4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ipilimumab.
<b>Purification method:</b>	This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
<b>Concentration:</b>	1.0 - 5.0 mg/ml
<b>Formulation:</b>	Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free.
<b>Purity:</b>	>95% by SDS-PAGE and HPLC
<b>Endotoxin:</b>	≤ 0.75 EU/mg as determined by the LAL method
<b>Storage:</b>	Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

### Background:

Ipilimumab biosimilar is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab biosimilar is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab biosimilar is produced in mammalian (Chinese hamster ovary) cell culture.